FRANKLIN, Ohio & BRONX, N.Y.--(BUSINESS WIRE)--NanoDetection Technology, Incorporated (NDT) and Oligomerix, Inc. today announced the execution of an exclusive worldwide license agreement. Under the terms of the agreement, NanoDetection has secured exclusive rights to develop and commercialize diagnostic tests utilizing a proprietary panel of nine Tau antibodies discovered by Oligomerix, Inc. and widely recognized for their scientific importance in neurodegenerative disease research. Oligomerix